Learning

February 22, 2019

Ribonucleic acid-based therapy for enhancing memory and cognition: LncRNA PCGEM1 increases Tissue inhibitor of metalloproteinases 2 (TIMP2) levels, improves cognition, and decreases age-associated decline in memory and learning, via down-regulation of its target genes, 22/February/2019, 11.45 pm

Introduction: What they say: A study from Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California 94305, USA;  Paul F. Glenn Center […]
February 15, 2019

Ribonucleic acid-based therapy for aging-associated diseases and Lifespan extension: LncRNA ANSR  inhibits the interaction of DBC1 with PARP1, increases the PARP1 activity, promotes DNA repair, augments tolerance against radiation, cancer, and aging, via down-regulation of its target gene, 15/February/2019, 7.16 am

Introduction: What they say A study from Department of Genetics, Paul F. Glenn Center for the Biology of Aging, Harvard Medical School, Boston, MA, USA; and […]
February 12, 2019

Ribonucleic acid-based therapy for enhancing memory and cognition: LncRNA HEIH  increases Tissue inhibitor of metalloproteinases 2 (TIMP2) levels, improves cognition, and decreases age-associated decline in memory and learning, via down-regulation of its target genes, 12/Februay/2019, 10.21 pm

Introduction: What they say: A study from Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California 94305, USA;  Paul F. Glenn Center […]
February 12, 2019

Ribonucleic acid-based therapy for enhancing memory and cognition: LncRNA  ILF3-AS1  increases Tissue inhibitor of metalloproteinases 2 (TIMP2) levels, improves cognition, and decreases age-associated decline in memory and learning, via down-regulation of its target genes, 12/Februay/2019, 9.56 pm

Introduction: What they say: A study from Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California 94305, USA;  Paul F. Glenn Center […]